On Thursday, Sept. 29, 2011, IFEZ signed an agreement with Dong-A Pharmaceutical to move in biopharmaceutical. Dong-A Pharmaceutical plans to build a biosimilar manufacturing facility for antibody drugs in Songdo International City on the 145,200 square meter site.